Jul 9 |
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
|
Jun 28 |
Kiniksa Pharmaceuticals files for $400M mixed shelf
|
Jun 17 |
Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
|
Jun 4 |
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
May 7 |
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
|
Apr 24 |
Kiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
Apr 24 |
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
|
Apr 24 |
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript
|
Apr 23 |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2024 Earnings Call Transcript
|
Apr 23 |
Kiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call Presentation
|